MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma

Modern Pathology

Volumn 9, Issue 12, 1996, Pages 1165-1169

  Ambros, Robert A ^a   Sheehan, Christine E ^a   Kallakury, Bhaskar V S ^a   Ross, Jeffrey S ^a   Malfetano, John ^a   Paunovich, Elizabeth ^a   Figge, James ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Endometrial carcinoma; MDM2 Gene; MDM2 Protein; p53 Gene; P53 Protein; Papillary serous carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 0030442560     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10, 1983
2. Deligdisch L: Morphologic correlates of host response in endometrial carcinoma. Am J Reprod Immunol 2:54, 1982
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R: Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6:93, 1982
4. Ambros RA, Vigna PA, Figge J, et al.: Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 73:1686, 1994
5. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG: p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 98:81, 1992
6. Kohler MF, Berchuck A, Davidoff AM, et al.: Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622, 1992
7. Jiko K, Sassano H, Ito K, et al.: Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 13:305, 1993
8. Isacson C, Levine R, Tashiro H, Cho KR, Hedrick L: p53 Gene mutations are common in uterine serous carcinomas and may occur as an early event in their pathogenesis (abstract). Mod Pathol 9:91A, 1996
9. Sherman ME, Bur ME, Kurman RJ: p53 In endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 26:1268, 1995
10. Enomoto T, Fujita M, Inoue M: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53: 1883, 1993
11. Ambros R, Ross JS, Kallakury BVS, et al.: p53 Gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemistry. Mod Pathol 8:441, 1995
12. Momand J, Zambetti P, Olsen DC, George D, Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237, 1992
13. Sherman ME, Bitterman P, Rosenshein NB, Kurman RJ: Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16:600, 1992
14. FIGO: Corpus cancer staging. Int J Gynecol Obstet 28:190, 1989
15. Zambetti P, Levine AJ: A comparison of the biologic activities of wild-type and mutant p53. FASEB J 7:855, 1993
16. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301, 1993
17. Barak Y, Juven T, Haffner R, Oren M: MDM2 expression is induced by wild type p53 activity. EMBO J 12:461, 1993
18. Xiao ZH, Chen J, Levine AJ, et al.: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694, 1995
19. Leach FS, Tokino T, Meltzer P, et al.: p53 Mutation and MDM2 amplification in soft tissue sarcomas. Cancer Res 53:2231, 1993
20. Reifenberger G, Liu L, Ichimur K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736, 1993
21. Marchetti A, Buttitta F, Girlando S, et al.: mdm2 Gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175:31, 1995
22. Cordon-Cardo C, Latres E, Drobnjak M, et al.: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794, 1994
23. Landers JE, Haines DS, Strauss JF III, George DL: Enhanced translation: A novel mechanism of mdm2 oncoprotein overexpression identified in human tumor cells. Oncogene 9:2745, 1994